{"nct_id":"NCT03277105","title":"A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","status_verified_date":"2025-04","start_date":"2017-10-27","start_date_type":"ACTUAL","primary_completion_date":"2019-06-27","primary_completion_date_type":"ACTUAL","completion_date":"2024-01-12","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["JNJ"]}